The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) published a 2017-18 Business Plan detailing how they will deliver Corporate Plan 2013-18, summarizing key achievements over the last year, and a strategic framework to face their challenges in the next. The business plan focuses on ten priorities including: ● a proposed model for future regulation of medicines and medical devices in the UK post-Brexit ● an international and enhanced national strategy for collaboration and engagement with key partners and stakeholders, and ● securing global supply chains for medicines and medical devices.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
